AtherosclerosisNCT06450561
Adherence to Secondary Prevention Guidelines for Cardiovascular Risk
An observational study of Atherosclerosis and Stroke, Ischemic, run by Consorci Sanitari de l'Alt Penedès i Garraf at 1 site in Spain.
Trial summary
The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atherosclerosis, Stroke, Ischemic, Acute Coronary Syndrome
- What is being tested?
- cardiovascular event
- How many people
- 129 participants
- Where
- 1 siteSpain
- Study dates
- 1 Mar 2024to 30 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients hospitalized due to a cardiovascular event
Who may be able to join
- Admitted to the cardiology, neurology, or general surgery departments
- With any of the following admission diagnoses:
- Non-ST-segment elevation acute coronary syndrome (NSTEACS) ST-segment elevation acute coronary syndrome (STEACS) Stable angina Unstable angina Non-ST-segment elevation myocardial infarction (NSTEMI) ST-segment elevation myocardial infarction (STEMI) Atherothrombotic ischemic stroke Lacunar stroke Peripheral artery disease Chronic ischemia of lower limbs Vascular ulcer due to arterial cause
Who cannot join
- Patients for whom lipid-lowering treatment is ruled out due to limited life expectancy
- Patients likely to die during hospitalization
- Patients who died during hospitalization
Trial locations and contacts
1 site in 1 country.
Spain1 site
Consorci Sanitari Alt Penedes i Garraf-Hospital Sant Camil
Sant Pere de Ribes, Barcelona, 08810
About this study
The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.
- Conditions
- Atherosclerosis, Stroke, Ischemic, Acute Coronary Syndrome, Ischemic Heart Disease, Peripheral Arterial Disease
- Being tested
- cardiovascular event
- Medical subject headings
- Atherosclerosis, Ischemic Stroke, Acute Coronary Syndrome, Myocardial Ischemia, Peripheral Arterial Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cardiovascular eventOther
In this single group observational trial the exposure of interest is a cardiovascular event.
| Study group | Role | What they receive |
|---|---|---|
| Patients hospitalized due to a cardiovascular event | Patients hospitalized due to a cardiovascular event including stroke, acute coronary syndrome, ischemic heart disease, or peripheral arterial disease Receives: Other: cardiovascular event |
What is being measured
The primary outcome is the main question the study is designed to answer.
patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge
Proportion of patients admitted for a cardiovascular event, warranting the initiation of secondary prevention with lipid-lowering agents, who are prescribed lipid-lowering treatment at discharge, adequate to reduce LDL by 50% or to below 55 mg/dL
Measured: Up to 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2024
- Study start1 Mar 2024
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AtherosclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 129 participants (actual)
Sponsor and investigators
- Lead sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lidia Tikhomirova, Principal investigator, CSAPG
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06450561
- Sponsor's protocol ID
- CSAPG-60
- Status last verified
- Dec 2025
- First submitted
- 3 Jun 2024
- Last updated
- 17 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adherence to Secondary Prevention Guidelines for Cardiovascular Risk
- ClinicalTrials.gov ID
- NCT06450561
- Acronym / sponsor ID
- CSAPG-60
- Conditions
- Atherosclerosis, Stroke, Ischemic, Acute Coronary Syndrome, Ischemic Heart Disease, Peripheral Arterial Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 129 participants (actual)
- Lead sponsor
- Consorci Sanitari de l'Alt Penedès i GarrafUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 10 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients hospitalized due to a cardiovascular event | – | Other: cardiovascular eventPatients hospitalized due to a cardiovascular event including stroke, acute coronary syndrome, ischemic heart disease, or peripheral arterial disease |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients hospitalized due to a cardiovascular event
Key inclusion criteria (3 listed)
- Admitted to the cardiology, neurology, or general surgery departments
- With any of the following admission diagnoses:
- Non-ST-segment elevation acute coronary syndrome (NSTEACS) ST-segment elevation acute coronary syndrome (STEACS) Stable angina Unstable angina Non-ST-segment elevation myocardial infarction (NSTEMI) ST-segment elevation myocardial infarction (STEMI) Atherothrombotic ischemic stroke Lacunar stroke Peripheral artery disease Chronic ischemia of lower limbs Vascular ulcer due to arterial cause
Key exclusion criteria (3 listed)
- Patients for whom lipid-lowering treatment is ruled out due to limited life expectancy
- Patients likely to die during hospitalization
- Patients who died during hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cardiovascular eventIn this single group observational trial the exposure of interest is a cardiovascular event. | Other | Patients hospitalized due to a cardiovascular event |
Primary outcome
patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge
Time frame: Up to 3 months
Proportion of patients admitted for a cardiovascular event, warranting the initiation of secondary prevention with lipid-lowering agents, who are prescribed lipid-lowering treatment at discharge, adequate to reduce LDL by 50% or to below 55 mg/dL
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2025.
- Individual participant dataSharing planned: Yes. IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
Related trials for Atherosclerosis
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lidia Tikhomirova principal investigator
CSAPG
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atherosclerosis and Stroke, Ischemic, run by Consorci Sanitari de l'Alt Penedès i Garraf at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge (time frame: Up to 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2025.